Pharmacogenomic associations of adverse drug reactions in asthma : systematic review and research prioritisation
A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.
| Errataetall: |
ErratumIn: Pharmacogenomics J. 2020 Jul 23;:. - PMID 32704026 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
The pharmacogenomics journal - 20(2020), 5 vom: 19. Okt., Seite 621-628 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Anti-Asthmatic Agents |
|---|
| Anmerkungen: |
Date Completed 07.07.2021 Date Revised 29.03.2024 published: Print-Electronic ErratumIn: Pharmacogenomics J. 2020 Jul 23;:. - PMID 32704026 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41397-019-0140-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305475800 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305475800 | ||
| 003 | DE-627 | ||
| 005 | 20240329232325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41397-019-0140-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM305475800 | ||
| 035 | |a (NLM)31949291 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a King, Charlotte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenomic associations of adverse drug reactions in asthma |b systematic review and research prioritisation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2021 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Pharmacogenomics J. 2020 Jul 23;:. - PMID 32704026 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 700 | 1 | |a McKenna, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Farzan, Niloufar |e verfasserin |4 aut | |
| 700 | 1 | |a Vijverberg, Susanne J |e verfasserin |4 aut | |
| 700 | 1 | |a van der Schee, Marc P |e verfasserin |4 aut | |
| 700 | 1 | |a Maitland-van der Zee, Anke H |e verfasserin |4 aut | |
| 700 | 1 | |a Arianto, Lambang |e verfasserin |4 aut | |
| 700 | 1 | |a Bisgaard, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a BØnnelykke, Klaus |e verfasserin |4 aut | |
| 700 | 1 | |a Berce, Vojko |e verfasserin |4 aut | |
| 700 | 1 | |a PotoČnik, Uros |e verfasserin |4 aut | |
| 700 | 1 | |a Repnik, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Carleton, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Daley, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Chew, Fook Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Chiang, Wen Chin |e verfasserin |4 aut | |
| 700 | 1 | |a Sio, Yang Yie |e verfasserin |4 aut | |
| 700 | 1 | |a Cloutier, Michelle M |e verfasserin |4 aut | |
| 700 | 1 | |a Den Dekker, Herman T |e verfasserin |4 aut | |
| 700 | 1 | |a Duijts, Liesbeth |e verfasserin |4 aut | |
| 700 | 1 | |a de Jongste, Johan C |e verfasserin |4 aut | |
| 700 | 1 | |a Dijk, F Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Flores, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez-Pacheco, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Somnath |e verfasserin |4 aut | |
| 700 | 1 | |a Basu, Kaninika |e verfasserin |4 aut | |
| 700 | 1 | |a Tantisira, Kelan G |e verfasserin |4 aut | |
| 700 | 1 | |a Verhamme, Katia M |e verfasserin |4 aut | |
| 700 | 1 | |a Celedón, Juan C |e verfasserin |4 aut | |
| 700 | 1 | |a Forno, Erick |e verfasserin |4 aut | |
| 700 | 1 | |a Canino, Glorisa |e verfasserin |4 aut | |
| 700 | 1 | |a Francis, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Pirmohamed, Munir |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Hawcutt, Daniel B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The pharmacogenomics journal |d 2001 |g 20(2020), 5 vom: 19. Okt., Seite 621-628 |w (DE-627)NLM11791813X |x 1473-1150 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:5 |g day:19 |g month:10 |g pages:621-628 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41397-019-0140-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 5 |b 19 |c 10 |h 621-628 | ||